Navigation Links
Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection
Date:2/6/2012

mercializing proprietary products principally for use in the hospital setting. For more information about Cadence, please visit www.cadencepharm.com.

Forward-Looking Statements Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Such statements include, without limitation, statements regarding: estimates of the number of vials of lot V005710 that currently remain in the marketplace and expectations regarding the supply of OFIRMEV. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Cadence's actual future results may differ materially from the company's current expectations due to the risks and uncertainties inherent in its business. These risks include, but are not limited to: Cadence's dependence on the successful commercialization of OFIRMEV, which is its only product; Cadence's ability to ensure an adequate and continued supply of OFIRMEV to meet anticipated market demand; the risk that if Cadence's contract manufacturers fail to meet its requirements for OFIRMEV, Cadence may be unable to meet market demand and may lose potential revenues; the potential that customers' perception of OFIRMEV or Cadence's relationships with its customers may be damaged by the recall; costs, re-stocking expenses and potential product liability claims that may be associated with the recall; the potential for additional recalls,  supply disruptions, or manufacturing changes for OFIRMEV; and other risks detailed under "Risk Factors" and elsewhere in Cadence's periodic reports and other filings made with the Securities and Exchange Commission from time to time. All forward-looking s
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. HealthTech Capital Leads Series A2 With Over $300,000 Investment in Cadence Biomedical
2. Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
3. Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock
4. Cadence Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results on November 3, 2011
6. Cadence Pharmaceuticals to Present at Three Investment Conferences During the Month of September 2011
7. Cadence Pharmaceuticals Reports Second Quarter 2011 Financial Results
8. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
9. Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Jefferies 2011 Global Healthcare Conference on June 9, 2011
11. Cadence, Inc. Announces Major Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... industry is expecting a busy summer this year, and ... Day weekend, more hotels and resorts are raising their ... according George Clarke, CEO of UMF Corporation, a developer ... hotels and resorts adopting environmental hygiene practices developed for ...
... SAN FRANCISCO, May 22, 2012  Boehringer Ingelheim announced ... the investigational compound tiotropium delivered once-daily via the ... moderate persistent asthma. The data were presented at ... Society (ATS 2012). Boehringer Ingelheim announced that a ...
Cached Medicine Technology:With Busy Summer Forecast Ahead, More Hotels Are Raising Hygiene Standards, Says UMF Corporation 2Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 2Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 3Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 4
(Date:4/24/2014)... 4/24/14) Dartmouth has been awarded one of 30 ... as a Lead Academic Participating Site in its new ... recipients are a select groups of investigators charged with ... cooperative groups., The NCTN grant system reflects recommendations from ... streamlines operations to achieve four goals:, Faster ...
(Date:4/23/2014)... (MGH) investigators may lead to greater availability and acceptability ... use of fecal material from healthy donors to ... ( C. difficile ) bacteria. In their ... Infectious Diseases , the researchers report that use of ... was as successful in curing recurrent C. difficile ...
(Date:4/23/2014)... M.D., scientific director at the National Institute of Arthritis ... the 2014 recipient of the Ross Prize in Molecular ... Molecular Medicine . The award will be given ... Sciences in Manhattan, followed by scientific presentations by Dr. ... the National Institutes of Health. , The award, which ...
(Date:4/23/2014)... enzyme pathway that helps prevent new cells from receiving ... has been directly linked to cancer and other diseases. ... near the end of cell division, the enzyme Cdc14 ... DNA are fully repaired before the parent cell distributes ... helps safeguard against some of the most devastating genome ...
(Date:4/23/2014)... In science, "simple and accessible detection methods that ... the resolution of a single cell inside that ... chemical engineer Chang Lu. , In the Royal ... Lu has announced that he and his coworkers ... subcellular location of a protein ( Chem. Sci. ...
Breaking Medicine News(10 mins):Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2
... Revenue Up 16% ... Cellulite Product Launch Targeted for Late Q1 ... Company Updates Guidance for Full Year 2007, HAYWARD, Calif., Nov. 6 ... the aesthetic,industry, today reported its financial results for the third quarter ended,September 30, ...
... Organizations Rapidly Identify High-Risk Cases, Provide ... BIRMINGHAM, Ala., Nov. 6 The ... DST Health Solutions announced that 16,organizations have ... helps organizations rapidly identify at-risk patients for,care ...
... - Continued progress in both core business segments supports ... Corporation,(Nasdaq: VRNM ), a leading developer of technologies ... of high-performance specialty,enzymes, today reported financial results for the ... "We are very pleased with the progress the Company ...
... Mass., Nov. 6 Biopure Corporation,(Nasdaq: BPUR ... public,offering of stock and warrants that raised net ... exercise of the warrants. Biopure,sold 19,377,500 new shares ... an,additional 19,377,500 shares, including 2,527,500 shares and 2,527,500,warrants ...
... group says , TUESDAY, Nov. 6 (HealthDay News) -- Standard ... been proposed by a team of Johns Hopkins experts, who ... comparisons and help improve patient safety. , "Hospitals are ... this is long overdue, the data is only helpful if ...
... for patients with sudden, life-threatening attacks, trial shows , , ... kind of medication has failed as treatment for the ... trial finds. , The drug, tezosentan, did not improve ... or cut their risk of death after acute ...
Cached Medicine News:Health News:Thermage Announces Third Quarter Financial Results 2Health News:Thermage Announces Third Quarter Financial Results 3Health News:Thermage Announces Third Quarter Financial Results 4Health News:Thermage Announces Third Quarter Financial Results 5Health News:Thermage Announces Third Quarter Financial Results 6Health News:Thermage Announces Third Quarter Financial Results 7Health News:Thermage Announces Third Quarter Financial Results 8Health News:Thermage Announces Third Quarter Financial Results 9Health News:Sixteen Organizations Implement ACG Rx-PM Predictive Modeling from Johns Hopkins University, DST Health Solutions 2Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 2Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 3Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 4Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 5Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 6Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 7Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 8Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 9Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 10Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 11Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 12Health News:Experimental Drug Fails Against Heart Failure 2Health News:Experimental Drug Fails Against Heart Failure 3
... latest in the Magnes line of biomagnetometer systems, ... full cortical coverage, provides the highest detector density ... of a wide range of neuronal activity. The ... detector configurations and can be equipped with radial ...
... for basic and advanced NCS, ... large 12.1" XGA (1024 x ... the latest in technology allow ... advanced NCS capabilities, advanced EMG ...
... is a non-invasive and painless method of ... Cadwell Laboratories manufactures two magnetic stimulation devices, ... Stimulator (HSMS). The Hight Speed MES-10 magnetic ... to 25 Hz at full power. Several ...
... are the latest innovation ... portable battery-powered EEG headboxes. ... new mechanical design, and ... standard MOBEE24plus and MOBEE32 ...
Medicine Products: